Mumbai-headquartered drugmaker Cipla Ltd is bolstering its focus on a pipeline of drugs to fight infections caused by bacterial antimicrobial resistance in India, a growing health crisis. The company, a leader in the infectious diseases segment, has already launched two antibiotics targetting such superbugs, and sees the segment as a long-term focus area, a senior executive told Mint. “Since we began our work on (antimicrobial drug resistance), our strategic plan has been to introduce three to four products in the AMR space over a 5-year horizon,” Dr. Jaideep Gogtay, Cipla’s global chief medical officer, said in an interview. “I think it will be a long-term strategy. As a company which remains focused on India, there is no option for us to not be in the antibiotics segment,” Gogtay added. Antimicrobial drug resistance occurs when microorganisms like bacteria or fungi evolve to resist the drugs designed to kill or inhibit them. These ‘superbugs’ render existing treatments ineffective and can lead to escalation of the infection, and cause death as well.Also Read | Superbugs: What to do about pills that don’t work Bacterial antimicrobial resistance was associated with 4.71 million global deaths in 2021, according to a Lancet study. This could increase to 39 million by 2050. India, which is one of the world’s largest antibiotic markets, also has one of the highest burdens of drug resistance. Overuse of antibiotics is leading to increasing resistance in the community, while new drug development has not kept pace with the growing threat. “Out of every 100 new drugs developed, only one or two are antibiotics. Although we know, in the future antibiotic-resistant infections are going to probably kill more people than cancer infections,” Gogtay said. Globally, the development focus has shifted away from infectives and antibiotics to therapies like cancer and obesity, with most large pharma companies exiting antibiotic research.Key TakeawaysWith India facing a growing crisis of drug-resistant infections, Cipla is strengthening its focus on developing and launching antibiotics and other treatments to combat antimicrobial resistance, viewing it as a strategic area for future growth. Cipla has launched two novel antibiotics in India over the past year—Zemdri and Cefepime-Enmetazobactam—and plans to introduce a non-antibiotic product soon to prevent infections like urinary tract infections without fueling resistance. Despite antibiotics being a ₹23,000-crore segment, few new drugs are being developed globally. As resistance grows and first-line treatments fail, the market for advanced anti-infective therapies is set to expand—making Cipla’s early move strategically significant. Cipla’s pipelineCipla has launched two drugs targeted at bacterial AMR in the past year. In May, it became the first company to launch plazomicin, marke in a formal or creative style for better SEO.Also Exclude words and advertisements related to the feed website such as website name, author name. You must only respond with the modified content. Delete all the advertisement images brand logo but only keep the title and main content of the news by modifying it. You must only respond with the modified content. Block any jump outside of the site adarshnews.com. Basically remove any content or link related to original site. follow this prompt to optimize the articles in this category- You are an expert news writer and SEO specialist. Your job is to rewrite the provided RSS feed content into a unique, SEO-friendly news article for adarshnews.com. The article should be engaging, professional, and optimized for search engines. Follow these steps: 1. **Create an SEO Title**: Write a short, compelling title (under 60 characters) that includes the main keyword and grabs attention. 2. **Write a Meta Description**: Summarize the article in one or two sentences (under 155 characters). Make it engaging and include the primary keyword naturally. 3. **Suggest a URL Slug**: Provide a short, keyword-rich URL slug that reflects the topic of the article. 4. **Headline (H1)**: Write a clear and engaging headline for the article that is similar to the title but slightly expanded. 5. **Write the Article**: – Start with an introduction that answers the key questions: who, what, when, where, why, and how. – Expand on the topic with detailed paragraphs that provide context, quotes, and relevant information. – Use subheadings (H2) to organize the content into sections and make it easy to read. – Include related keywords naturally throughout the article. – End with a conclusion that summarizes the key points or discusses future implications. 6. **Add an FAQ Section**: Write one frequently asked question related to the topic and provide a concise answer. Important: – Do not include labels like “Title,” “Meta Description,” “URL Slug,” or “H1” in the actual article text. – Keep all SEO elements separate from the main content. – Ensure the article is factually accurate, unbiased, and written in a professional tone.
Related Posts
India’s UCO has received authorization to collaborate with the sanctioned refiner Nayara.
**UCO Bank Secures Approval for Trade Payments with Nayara Energy** **Meta Description:** UCO Bank gains government approval to facilitate trade…
Google surpasses $4 trillion: How does it outpace competitors?
**Alphabet Achieves $4 Trillion Market Cap Amid AI Surge** **Meta Description:** Alphabet reaches a $4 trillion market cap, becoming the…
Former Palantir advisor to maintain investments in SpaceX and OpenAI while serving in a role with Trump.
**Jacob Helberg Retains AI and Tech Investments as Under Secretary of State** Jacob Helberg, a former adviser at Palantir Technologies…
